Treatment Regimens and Recommendations for HIV/HCV Coinfection
Experts discuss the management of drug-drug interactions in patients receiving treatment for HIV and HCV coinfection.
Experts discuss the management of drug-drug interactions in patients receiving treatment for HIV and HCV coinfection.
Researchers compared the safety and efficacy of sofosbuvir plus ledipasvir vs pegylated interferon and ribavirin for 12 weeks in patients with thalassemia major and hepatitis C virus genotype 1 or 4.
A new organ dysfunction scoring system that predicts in-hospital mortality was validated in critically ill children admitted to the pediatric intensive care unit.
Azithromycin is more likely to reduce exacerbations of COPD among patients with antibodies against Helicobacter pylori.
The World Health Organization published a position paper with updated recommendations on the use of the hepatitis B vaccine regarding target groups, immunization schedules, and storage and distribution.
A recent update of a meta-analysis evaluating treatments for latent tuberculosis infection found that several regimens, including those with a low pill burden and short duration, were safe and effective.
While Mycoplasma genitalium is emerging as one of the most common causes of sexually transmitted infections, and is often underrecognized and treated with ineffective antibiotics.
A newly identified genetic polymorphism was associated with increased rates of mortality and severe clinical outcomes from influenza infection and lower levels of resident lung CD8+ T cells, particularly in individuals of European descent.
Epidemiological data demonstrate a link between HCV infection and cardiovascular disease, whereas treatment studies suggest viral eradication may lower the risk for cardiovascular morbidity and mortality.
New WHO guidelines address the issue of how to manage pretreatment human immunodeficiency virus drug resistance (HIVDR) in countries where the prevalence of HIVDR is 10% or higher.